News

Healio22s
‘First of a new class’: FDA approves upadacitinib to treat giant cell arteritis
The FDA has approved the Janus kinase inhibitor upadacitinib for the treatment of giant cell arteritis in adults, the first ...
MPR48m
FDA Approves Rinvoq for Giant Cell Arteritis
The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 SELECT-GCA trial.
Le Lézard5h
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
AbbVie today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA).1 This comes ...